Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in sev...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacol Ther
Main Authors: Amstutz, Ursula, Henricks, Linda M., Offer, Steven M., Barbarino, Julia, Schellens, Jan H.M., Swen, Jesse J., Klein, Teri E., McLeod, Howard L., Caudle, Kelly E., Diasio, Robert B., Schwab, Matthias
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5760397/
https://ncbi.nlm.nih.gov/pubmed/29152729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.911
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares